Want to see KPTI full AI Analyst Report?
KPTI Stock Chart & Stats
$8.61
-$0.04(-5.28%)
At close: 4:00 PM EST
$8.61
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.65 - $10.99
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$178.24M
Enterprise Value$277.69
Total Cash (Recent Filing)$90.85M
Total Debt (Recent Filing)$230.87M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Jul 30, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.84
Shares Outstanding22,662,943
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside50.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.08
Revenue Forecast (FY)$137.21M
Bulls Say, Bears Say
Bulls Say
High Gross MarginExceptional product-level economics (≈96% gross margin) indicate low incremental manufacturing costs for XPOVIO. That structural margin gives the company flexibility to invest in R&D and commercialization as revenue scales, and supports long-term margin sustainability if uptake grows.
Robust Phase III DataClear, statistically strong Phase III efficacy (robust spleen responses and an OS signal) materially improves regulatory and commercial leverage. Durable late‑stage data increases probability of label expansion, physician adoption, and payer support, underpinning long-term market opportunity.
Pipeline Progress And Enrollment CompleteCompleted enrollment in EC042 plus encouraging SIENDO benchmarks diversify value drivers beyond current indications. A successful readout and subsequent approvals would broaden addressable markets and reduce reliance on a single product for sustained revenue growth.
Bears Say
Negative Shareholders' EquityDeeply negative equity materially weakens financial flexibility and increases refinancing and going‑concern sensitivity. Structurally, this limits the company's ability to withstand setbacks, pursue opportunistic investments, or access non‑dilutive capital without elevated risk or cost.
Persistent Cash BurnSustained negative operating and free cash flow (~-$59M TTM) means the business consumes cash to operate. Over months this constrains reinvestment and commercialization scale, and creates structural dependence on external financing or milestone receipts to fund ongoing R&D and sales.
Short Cash RunwayReported cash providing runway only into late Q3 2026 creates a near-term funding cliff that can force dilutive financings or urgent partnerships. This timing risk can influence strategic choices and distract management from long-term commercialization execution if capital is not secured.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.65 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $178.24M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on May 14, 2026. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.417 by $0.177.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -1.31.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,662,943 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.417. Following the earnings report the stock price went up 0.565%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (50.99% Upside)
$13.00 (50.99% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Stock 12 Month Forecast
Average Price Target
$13.00
▲(50.99% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
3.66% Insiders
18.52% Mutual Funds
<0.01% Other Institutional Investors
68.41% Public Companies and
Individual Investors